As of November 8, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Biofrontera Inc. The largest reported stake is Deutsche Balaton Aktiengesellschaft's, at 19.99%. 7 filings are on record since July 25, 2025 (Schedule 13D/A, September 19, 2025).
Sell to companies like Biofrontera Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Rosalind Advisors, Inc. · Sole voting: 0 · Shared voting: 16,801,629 · Sole dispositive: 0 · Shared dispositive: 16,801,629 · SCHEDULE 13G/A, 2026-08-12
- · Holder: Rosalind Advisors, Inc. · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Orin Hirschman · Percent: 7.9% · SCHEDULE 13G/A
- · Holder: Rosalind Advisors, Inc. · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Deutsche Balaton Aktiengesellschaft · Percent: 19.99% · SCHEDULE 13D/A
Biofrontera Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-25. 3 holders' latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 19.99% | 2,552,230 | SCHEDULE 13D/A, 2025-09-19 | 2025-09-16 | |
| Rosalind Advisors, Inc. | 9.9% | 16,801,629 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| 7.9% | 915,210 | SCHEDULE 13G/A, 2026-01-28 | 2025-12-31 |
Holding shares or following this stake? See who's behind Biofrontera Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Biofrontera Inc. and the records around it.
Biofrontera Inc. elsewhere on the record
- Form D filing Jul 2025
- Who owns it
Companies that share a holder
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), FENNEC PHARMACEUTICALS INC. (Aug 2026)
- Orin Hirschman also filed stake reports on 46 other companies: ASPEN AEROGELS, INC. (Oct 2026), Bionano Genomics, Inc. (Oct 2026), FENNEC PHARMACEUTICALS INC. (Oct 2026)
Watch Biofrontera Inc.
Get an email when Biofrontera Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Biofrontera Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Biofrontera Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Biofrontera Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 0 | 16,801,629 | 0 | 16,801,629 | SCHEDULE 13G/A, 2026-08-12 |
| Salamon Steven A J | 0 | 16,801,629 | 0 | 16,801,629 | SCHEDULE 13G/A, 2026-08-12 |
| Aharon Gil | 0 | 16,801,629 | 0 | 16,801,629 | SCHEDULE 13G/A, 2026-08-12 |
| Rosalind Master Fund L.P. | 0 | 16,801,629 | 0 | 16,801,629 | SCHEDULE 13G/A, 2026-08-12 |
The latest filing identifies Biofrontera Inc. by CUSIP 09077D209 and gives its principal executive office as 120 PRESIDENTIAL WAY, WOBURN, MA 01801 (SCHEDULE 13G/A, 2026-08-12).
Purpose of Transaction (Item 4)
Deutsche Balaton Aktiengesellschaft
Explanatory Note: There is no agreement among the Reporting Persons, written or oral, with respect to the acquisition, ownership, voting or disposition of any securities of the Issuer, and the Reporting Persons disclaim the existence of any group among them within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Act"), or the rules and regulations of the Securities and Exchange Commission ("SEC") promulgated thereunder. Except as otherwise set forth herein, all percentages herein are based on 10,668,442 shares of common stock outstanding as reported by the Issuer as of August 12, 2025, in its Quarterly Report on Form 10-Q filed on August 13, 2025, plus the 2,093,346 shares of the Issuer's common stock issuable upon conversion of BFAG's shares of Series D Preferred Stock. The information set forth in Item 3 of this Amendment No. 4 to Schedule 13D is hereby incorporated by reference into this Item 4. Prior to November 2, 2021, the Issuer was a wholly owned subsidiary of BFAG. On November 2, 2021, the Issuer consummated its initial public offering ("IPO") of 3,600,000 units, each consisting of (i) one share of common stock of the Issuer and (ii) one warrant entitling the holder to purchase one share of the Issuer's common stock at an exercise price of $5.00 per share, and such equity securities were registered under Section 12(b) of the Act. Immediately following the IPO, BFAG owned 8,000,000 shares of common stock, or approximately …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-09-19; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-25 | Deutsche Balaton Aktiengesellschaft | 4.86% | SCHEDULE 13D/A |
| 2025-08-11 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2025-09-19 | Deutsche Balaton Aktiengesellschaft | 19.99% | SCHEDULE 13D/A |
| 2025-11-12 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-01-28 | Orin Hirschman | 7.9% | SCHEDULE 13G/A |
| 2026-02-11 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-08-12 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
Questions about who owns Biofrontera Inc.
Who owns Biofrontera Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Biofrontera Inc.: Deutsche Balaton Aktiengesellschaft (19.99%, Schedule 13D/A, filed 2025-09-19), Rosalind Advisors, Inc. (9.9%, Schedule 13G/A, filed 2026-08-12) and Orin Hirschman (7.9%, Schedule 13G/A, filed 2026-01-28).
Who are the largest shareholders of Biofrontera Inc.?
By the share each holder's latest filing reports, the largest holders of Biofrontera Inc. on this page are Deutsche Balaton Aktiengesellschaft (19.99%), Rosalind Advisors, Inc. (9.9%) and Orin Hirschman (7.9%).
When did Deutsche Balaton Aktiengesellschaft buy into Biofrontera Inc.?
The filings give report dates, not purchase dates. The earliest filing from Deutsche Balaton Aktiengesellschaft on this page is the Schedule 13D/A, filed 2025-07-25, reporting 4.86%; its latest, Schedule 13D/A filed 2025-09-19, reports 19.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Biofrontera Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 11, 2025 | Form D, private offering | $11M sold | Form D page | Source |
| December 5, 2024 | Form D, private offering | $4.20M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Biofrontera Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.